A Phase 2 interventional study of Voclosporin in Focal Segmental Glomerulosclerosis, sponsored by Aurinia Pharmaceuticals Inc.. Terminated at 23 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2018, is one of 29 in phase 2, and was the 36th registered.
106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.
Browse Glomerulosclerosis, Focal Segmental studies →18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 34 more countries
Ages 12+
Akebia Therapeutics · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, Germany, Italy and 2 more countries
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 31 · Phase 3 5 · Phase 4 4
First in 1996; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.
Median enrollment 30 across the 56 interventional studies, 252 across the 13 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 1 study filed under Glomerulosclerosis, Focal Segmental — fewer than ten, so there is no comparison to draw.
10 of the studies in Glomerulosclerosis, Focal Segmental with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01094327University of MiamiProteinuria in Pre and Post Transplant | 2026-11-30 |
| NCT06500702SanofiA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | 2026-12-23 |
| NCT07219121Travere Therapeutics, Inc.Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | 2027-03 |
| NCT05583942Northwell HealthA Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) | 2027-03-01 |
| NCT05588063Northwell HealthtaVNS for FRNS in Children | 2027-03-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
The aim of the current study to assess the efficacy of voclosporin in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin over 24 weeks in subjects with FSGS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current or medical history of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: Maximum dose of 3 capsules (7.9mg) BID Cohort 2 Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.
Drug: Voclosporin
Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID). The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1.
Proportion of Subjects With Remission of Proteinuria
Complete remission OR Partial remission
Time frame: 24 weeks
Proportion of Subjects With Complete Remission or Partial Remission of Proteinuria
Complete remission or partial remission of proteinuria
Time frame: Weeks 8 and 12
Proportion of Subjects With Complete Remission of Proteinuria
Complete remission of proteinuria
Time frame: Weeks 8, 12, and 24
Proportion of Subjects With Reduction of Proteinuria
Reduction of proteinuria
Time frame: Weeks 8, 12, and 24
Proportion of Subjects With Partial Remission of Proteinuria
Partial remission of proteinuria
Time frame: Weeks 8, 12, and 24
Time to First Occurrence of Complete or Partial Remission of Proteinuria
Complete OR partial remission of proteinuria
Time frame: Up to 26 weeks
Time to First Occurrence of Complete Remission of Proteinuria
Complete remission of proteinuria
Time frame: Up to 26 weeks
Time to First Occurrence of Partial Remission of Proteinuria
Partial remission of proteinuria
Time frame: Up to 26 weeks
Time to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline
50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline
Time frame: Up to 26 weeks
Duration of Reduced Urine Protein Creatinine Ratio (UPCR)
Duration of reduced Urine Protein Creatinine Ratio (UPCR)
Time frame: Up to 26 weeks
Change From Baseline in Urine Protein Creatinine Ratio (UPCR)
Change from baseline in Urine Protein Creatinine Ratio (UPCR)
Time frame: Weeks 2,4,8,12,18,24
Proportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula
Time frame: Weeks 2,4,8,12,18,24
Proportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)
Increase in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Week 24 to Week 26
Change in Urine Protein Creatinine Ratio (UPCR)
Change in Urine Protein Creatinine Ratio (UPCR)
Time frame: Week 24 and Week 26
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in estimated Glomerular Filtration Rate (eGFR)
Time frame: Week 24 and Week 26
Change From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)
Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)
Time frame: Weeks 2,4,8,12,18,24
Quality of Life Assessments
Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures
Time frame: Week 24
Quality of Life Assessments
Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)
Time frame: Week 24
Safety and Tolerability (Treatment-Emergent Adverse Events)
Incidence and number of treatment-emergent adverse events
Time frame: 24 weeks
Renal Biopsy
Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients
Time frame: 24 weeks
| Milestone | Voclosporin Cohort 1 | Voclosporin Cohort 2 |
|---|---|---|
| Started | 5 | 0 |
| Week 1: 7.9 mg twice daily | 5 | 0 |
| Week 2: 15.9 mg twice daily | 5 | 0 |
| Weeks 3 - 24: 23.7 mg twice daily | 5 | 0 |
| Completed | 4 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Complete remission OR Partial remission
No measurements were reported for this outcome.
Complete remission or partial remission of proteinuria
No measurements were reported for this outcome.
Complete remission of proteinuria
No measurements were reported for this outcome.
Reduction of proteinuria
No measurements were reported for this outcome.
Partial remission of proteinuria
No measurements were reported for this outcome.
Complete OR partial remission of proteinuria
No measurements were reported for this outcome.
Complete remission of proteinuria
No measurements were reported for this outcome.
Partial remission of proteinuria
No measurements were reported for this outcome.
50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline
No measurements were reported for this outcome.
Duration of reduced Urine Protein Creatinine Ratio (UPCR)
No measurements were reported for this outcome.
Change from baseline in Urine Protein Creatinine Ratio (UPCR)
No measurements were reported for this outcome.
Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula
No measurements were reported for this outcome.
Increase in Estimated Glomerular Filtration Rate (eGFR)
No measurements were reported for this outcome.
Change in Urine Protein Creatinine Ratio (UPCR)
No measurements were reported for this outcome.
Change in estimated Glomerular Filtration Rate (eGFR)
No measurements were reported for this outcome.
Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)
No measurements were reported for this outcome.
Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures
No measurements were reported for this outcome.
Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)
No measurements were reported for this outcome.
Incidence and number of treatment-emergent adverse events
No measurements were reported for this outcome.
Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients
No measurements were reported for this outcome.
Collected over Day 1 to Week 26. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voclosporin Cohort 1: Week 1 | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Voclosporin Cohort 1: Week 2 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Voclosporin Cohort 1: Weeks 3-24 | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Voclosporin Cohort 2 | — | — | — |
| Event | Voclosporin Cohort 1: Week 1 | Voclosporin Cohort 1: Week 2 | Voclosporin Cohort 1: Weeks 3-24 | Voclosporin Cohort 2 |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/5 | 0/5 | 1/5 | — |
| Acute Kidney InjuryRenal and urinary disorders | 0/5 | 0/5 | 1/5 | — |
| Event | Voclosporin Cohort 1: Week 1 | Voclosporin Cohort 1: Week 2 | Voclosporin Cohort 1: Weeks 3-24 | Voclosporin Cohort 2 |
|---|---|---|---|---|
| Glomerular filtration rate decreasedInvestigations | 0/5 | 0/5 | 3/5 | — |
| Blood creatine phosphokinase increasedInvestigations | 1/5 | 0/5 | 2/5 | — |
| HeadacheNervous system disorders | 0/5 | 0/5 | 2/5 | — |
| DizzinessNervous system disorders | 0/5 | 0/5 | 1/5 | — |
| ParaesthesiaNervous system disorders | 0/5 | 0/5 | 1/5 | — |
| TremorNervous system disorders | 0/5 | 0/5 | 1/5 | — |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/5 | 1/5 | — |
| Gingival bleedingGastrointestinal disorders | 0/5 | 0/5 | 1/5 | — |
| VomitingGastrointestinal disorders | 0/5 | 0/5 | 1/5 | — |
| PyrexiaGeneral disorders | 0/5 | 0/5 | 1/5 | — |
Trial ended prematurely before any patients were enrolled into Cohort 2
| Age, Continuous(years) | Voclosporin Cohort 1 | Voclosporin Cohort 2 | Total |
|---|---|---|---|
| Mean | 36.2 ± 20.71 | — | 36.2 ± 20.71 |
| Sex: Female, Male(Participants) | Voclosporin Cohort 1 | Voclosporin Cohort 2 | Total |
|---|---|---|---|
| Female | 2 | — | 2 |
| Male | 3 | — | 3 |
| Ethnicity (NIH/OMB)(Participants) | Voclosporin Cohort 1 | Voclosporin Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | — | 2 |
| Not Hispanic or Latino | 3 | — | 3 |
| Unknown or Not Reported | 0 | — | 0 |
| Race (NIH/OMB)(Participants) | Voclosporin Cohort 1 | Voclosporin Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 |
| Asian | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Black or African American | 1 | — | 1 |
| White | 3 | — | 3 |
| More than one race | 0 | — | 0 |
| Unknown or Not Reported | 1 | — | 1 |
| Region of Enrollment(participants) | Voclosporin Cohort 1 | Voclosporin Cohort 2 | Total |
|---|---|---|---|
| United States | 3 | — | 3 |
| Dominican Republic | 2 | — | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in May 2020, 22 months.
Results were first posted in Sep 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Glomerulosclerosis, Focal Segmental →
Aurinia Pharmaceuticals Inc.